Transition From Biomarkers To Surrogate Endpoints Will Be Subcmte. Topic
This article was originally published in The Pink Sheet Daily
Executive Summary
The subcommittee will focus on the planning and process of the transition from biomarkers to surrogate endpoints for drugs under FDA’s “Critical Path” initiative. Updating approved drug labeling to include pharmacogenetic information will also be discussed at the Nov. 3-4 meeting.
You may also be interested in...
FDA Science Board Will Look At “Future Plans” For “Critical Path” At Nov. 5 Meeting
The meeting is one of several by the agency to discuss the drug development initiative. The final report of FDA’s good manufacturing practices initiative will also be reviewed.
FDA Science Board Will Look At “Future Plans” For “Critical Path” At Nov. 5 Meeting
The meeting is one of several by the agency to discuss the drug development initiative. The final report of FDA’s good manufacturing practices initiative will also be reviewed.
FDA Initiative Encourages Use Of Imaging Technologies To Identify Biomarkers
An FDA working group will develop guidance on the use of imaging to speed drug development. Locating the biomarkers will require coordination between manufacturers and the imaging industry.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: